Market Research Logo

Status Epilepticus - Pipeline Review, H2 2015

Status Epilepticus - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Status Epilepticus - Pipeline Review, H2 2015’, provides an overview of the Status Epilepticus’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Status Epilepticus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Status Epilepticus and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Status Epilepticus
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Status Epilepticus and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Status Epilepticus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Status Epilepticus pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Status Epilepticus
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Status Epilepticus pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Status Epilepticus Overview
Therapeutics Development
Pipeline Products for Status Epilepticus - Overview
Pipeline Products for Status Epilepticus - Comparative Analysis
Status Epilepticus - Therapeutics under Development by Companies
Status Epilepticus - Therapeutics under Investigation by Universities/Institutes
Status Epilepticus - Pipeline Products Glance
Late Stage Products
Early Stage Products
Status Epilepticus - Products under Development by Companies
Status Epilepticus - Products under Investigation by Universities/Institutes
Status Epilepticus - Companies Involved in Therapeutics Development
Ligand Pharmaceuticals, Inc.
Sage Therapeutics
Status Epilepticus - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ADD-405008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMPX-0079 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fosphenytoin sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAGE-217 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAGE-547 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAGE-689 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TG-4155 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Status Epilepticus - Recent Pipeline Updates
Status Epilepticus - Dormant Projects
Status Epilepticus - Product Development Milestones
Featured News & Press Releases
Jun 09, 2015: SAGE Therapeutics Announces Positive Top-Line Data in Exploratory Trial of SAGE-547 in Postpartum Depression
May 14, 2015: SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus
Apr 22, 2015: Ligand Earns Milestone from SAGE Therapeutics for SAGE-547
Apr 20, 2015: SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol to Evaluate SAGE-547 in Patients with Super-Refractory Status Epilepticus
Apr 09, 2015: SAGE Therapeutics presents Phase 1/2 clinical trial data on SAGE-547 at Upcoming Scientific Conferences
Apr 09, 2015: SAGE Therapeutics presents preclinical data on SAGE-689 at Upcoming Scientific Conferences
Apr 02, 2015: SAGE Therapeutics Announces Positive End-of-Phase 2 Meeting With FDA and Planned Initiation of SAGE-547 Global Phase 3 Trial in Mid-2015
Jan 09, 2015: SAGE Therapeutics Reports Updated Data from Ongoing Clinical Trial and Emergency Use Program of SAGE-547 in Patients with Super-Refractory Status Epilepticus
Nov 10, 2014: SAGE Therapeutics Reports Positive Top-Line Phase 2 Data of SAGE-547 in Patients With Super-Refractory Status Epilepticus
Nov 03, 2014: First Evaluation of SAGE-547 to Treat Super-Refractory Status Epilepticus in Children Published in Annals of Neurology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Status Epilepticus, H2 2015
Number of Products under Development for Status Epilepticus - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Status Epilepticus - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015
Status Epilepticus - Pipeline by Sage Therapeutics, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Status Epilepticus Therapeutics - Recent Pipeline Updates, H2 2015
Status Epilepticus - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Status Epilepticus, H2 2015
Number of Products under Development for Status Epilepticus - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report